Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy
- 2 February 2011
- Vol. 60 (9), 1269-1277
- https://doi.org/10.1136/gut.2010.226225
Abstract
Objective To investigate the evolution of hepatitis B virus (HBV) quasispecies (QS) within the reverse transcriptase (RT) region during the early stage of entecavir treatment and its impact on virological response, and to compare evolutionary patterns under different selective pressures. Methods 31 patients with chronic hepatitis B receiving entecavir (17 responders and 14 partial responders according to the HBV DNA levels at week 48) and 25 patients receiving lamivudine (14 responders and 11 non-responders) as controls were included. An average of 26 clones (2892 total from both groups) spanning the RT region per sample was sequenced. Results QS complexity and diversity, in addition to alanine aminotransferase and HBV DNA levels, were comparable between responders and partial responders at baseline. However, QS complexity in responders at week 4 was statistically lower than that in partial responders at the nucleotide level (0.6494 vs 0.7723, p=0.039). Net changes in diversity as well as the viral nucleotide substitution rate of responders were higher than those of partial responders, and both correlated with virological responses at both week 48 and the final visit (mean: 28 months). A preliminary model of QS evolution variables predicted 16 of 17 responders and 13 of 14 partial responders in the entecavir group. Despite significant differences between responders to entecavir and responders to lamivudine at week 4, the characteristics of QS were quite similar between partial responders to entecavir and non-responders to lamivudine. Conclusions The evolutionary patterns of HBV RT QS differ between responders and partial responders during the early stage of entecavir treatment. Characteristics of HBV QS evolution during the first 4 weeks contribute to the prediction of long-term virological responses. The similar patterns of HBV RT QS in partial responders and non-responders receiving different nucleoside analogues may imply a novel mechanism of drug resistance, which warrants further investigation.Keywords
This publication has 33 references indexed in Scilit:
- 20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTSJournal of Hepatology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacyJournal of Hepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 UpdateClinical Gastroenterology and Hepatology, 2008
- Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis BGastroenterology, 2007
- Quasispecies and its impact on viral hepatitisVirus Research, 2007
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BThe New England Journal of Medicine, 2006
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJournal of Viral Hepatitis, 2004
- Hepatitis B virus genomic heterogeneity: variation between quasispecies may confound molecular epidemiological analyses of transmission incidentsJournal of Viral Hepatitis, 1997